CD40LG and in situ carcinoma: By pooling a large number of studies with information regarding the IgM status, we found that in MS patients, the overall prevalence of an ITMS was 29.0%, and it was higher in RRMS (40.1%) than in CIS patients (23.8%, p < 0.0001).